Your browser doesn't support javascript.
loading
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden, A D; Young, G S; Setayesh, K; Muzikansky, A; Klufas, R; Ross, G L; Ciampa, A S; Ebbeling, L G; Levy, B; Drappatz, J; Kesari, S; Wen, P Y.
Affiliation
  • Norden AD; Department of Neurology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, SW430B, 44 Binney St., Boston, MA 02115, USA. anorden@partners.org
Neurology ; 70(10): 779-87, 2008 Mar 04.
Article in En | MEDLINE | ID: mdl-18316689
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioma / Antibodies, Monoclonal / Neoplasm Recurrence, Local Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Language: En Journal: Neurology Year: 2008 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioma / Antibodies, Monoclonal / Neoplasm Recurrence, Local Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Language: En Journal: Neurology Year: 2008 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos